Trial Profile
Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody Durvalumab (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Cediranib (Primary) ; Durvalumab (Primary) ; Olaparib (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Small cell lung cancer; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 14 Feb 2024 Planned primary completion date changed from 30 Jan 2024 to 30 Dec 2024.
- 24 Oct 2023 Results presented at the 48th European Society for Medical Oncology Congress
- 01 Dec 2022 Planned End Date changed from 30 Dec 2024 to 30 Dec 2025.